ABS0690 EFFECTIVENESS OF TOCILIZUMAB IN STROKES IN PATIENTS WITH GIANT CELL ARTERITIS. SPANISH MULTICENTER STUDY OF CLINICAL PRACTICE

Le résumé fourni par la source

Background: Stroke is a feared complication of giant cell arteritis (GCA). Tocilizumab (TCZ) has shown efficacy and safety in large-vessel vasculitis (LVV) including GCA. Objectives: To assess the effectiveness of TCZ in the stroke associated with GCA regarding to: i) prevent the appearance of new strokes, and ii) improve stroke if present. Methods: Observational, multicenter study of 471 patients with GCA treated with TCZ. Patients were diagnosed with GCA accordingly to: a) American College of Rheumatology (ACR) criteria, and/or b) positive biopsy of temporal artery, and/or c) the presence of imaging techniques consistent with LVV. Patients were divided into two groups: i) with, and ii) without stroke. All patients in whom stroke was diagnosed had lesions on computed tomography (CT) and/or magnetic resonance imaging (MRI) scans that were read by a neuroradiologist and correlated clinically by a neurologist. Results: 471 (342 females; 72.1±9.1 years) patients with GCA treated with TCZ were included. Stroke at any time (before and after TCZ) were observed in 7 (1.5%) patients. In 5 of them stroke was present at TCZ initiation. One patient had a stroke previously with complete recovery and another patient had a stroke after starting TCZ and died. Main features of GCA with and without stroke are shown in Table 1. Patients with stroke were predominantly male and were or had been smokers. At TCZ initiation 5 patients had a stroke in vertebrobasilar territory. Only one patient suffered lacunar infarctions after TCZ initiation, while the 5 patients who had a stroke at TCZ initiation experienced progressive improvement. Conclusion: Stroke in GCA is an infrequent manifestation of GCA and occur mainly in the vertebrobasilar territory. TCZ might prevent the appearance of new strokes and appears to aid recovery in existing ones. REFERENCES: NIL . Acknowledgements: NIL . Disclosure of Interests: Carmen Secada-Gómez: None declared , Javier Loricera Roche, Galápagos, Novartis, UCB Pharma, MSD, Celgene, Astra Zeneca, and Grünenthal, Janssen, Abbvie, Roche, Novartis, MSD, UCB Pharma, Celgene, Lilly, Pfizer, Galápagos, Clara Moriano Morales: None declared , Santos Castañeda BMS, Eli-Lilly, Roche, Gedeon-Richter, Grünenthal Pharma and UCB, MSD and Pfizer, Francisco Javier Narváez Garcia: None declared , Vicente Aldasoro: None declared , Rafael B Melero-González: None declared , Isabel de la Morena Barrio: None declared , Iván Ferraz-Amaro Abbvie, Pfizer, Roche, Sanofi, Celgene, and MSD, Abbvie, MSD, Janssen, and Roche, Ricardo Blanco AbbVie, Pfizer, Roche, GSK, Lilly, UCB, Bristol-Myers, Novartis, Janssen, UCB and MSD, AbbVie, MSD, and Roche. © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.